Sanara MedTech (NASDAQ:SMTI) today announced its financial results for the fourth quarter and full year ended December 31, 2025, marking the first time the company has surpassed the $100 million annual revenue threshold.
Full-year net revenue rose 19% year-over-year to $103.1 million, a testament to the company’s successful penetration into the surgical and chronic wound care markets.
Alongside this top-line growth, Sanara reported an adjusted EBITDA of $17 million, reflecting its ability to scale operations while maintaining healthy operational margins.
The company’s growth engine is currently powered by its surgical portfolio, particularly BIASURGE™, an advanced surgical rinse.
Sanara also highlighted a significant commercial win with a new Vizient Innovative Technology contract, which is expected to accelerate BIASURGE adoption across Vizient’s extensive network of member hospitals.
This GPO alignment provides a streamlined pathway for surgical teams to access Sanara's tissue repair technologies, reducing the administrative hurdles typically associated with new product value analysis.
Looking toward the future, Sanara is heavily investing in its next-generation pipeline.
The company is preparing for the U.S. commercial launch of OsStic, a highly anticipated bone adhesive, in the first quarter of 2027, pending FDA 510(k) clearance.
To support this and other biological innovations, Sanara increased its R&D investment throughout 2025, focusing on technologies that improve patient outcomes in complex orthopedic and soft tissue procedures.
Management also expressed high confidence in the current trajectory by reaffirming its 2026 revenue guidance of $116 million to $121 million.
This forecast represents a projected growth rate of approximately 13% to 17%, driven by a larger direct sales force and deeper hospital penetration.